CJC-1295 Cost in the US

There is no single price for CJC-1295

If you search “CJC-1295 cost,” you’ll get numbers that don’t seem to belong to the same product: a research vial for under $50, a monthly clinic program for several hundred dollars, a concierge service quoting four figures. None of those is wrong, and the spread isn’t a question of who’s overcharging. The price of CJC-1295 tracks the route and the oversight — what’s wrapped around the molecule — far more than the molecule itself.

That’s true of most peptides. But CJC-1295 carries an extra complication that makes its pricing uniquely messy in 2026: it does not have a clean legal supply. Most of the peptides people compare it to are either FDA-approved drugs or are moving through the current reclassification process toward legal compounding. CJC-1295 is in neither group. Understanding that is the difference between reading the price tags correctly and getting talked into the wrong thing.

Note: This page is about cost and value, not how to dose or where to source. We don’t publish dosing protocols or sourcing instructions for unapproved injectables. If you’re weighing this therapy, the cost conversation belongs with a licensed provider who can evaluate you first.

The three price worlds you’re actually comparing

Almost every CJC-1295 figure online sits in one of three buckets. They are not interchangeable.

Research-chemical vials — roughly $45 to $95 each. These are the cheapest numbers you’ll see, and they’re the most misleading. Vendors sell them labeled “for research use only,” with no prescription, no compounding pharmacy, no clinical oversight, and no enforceable guarantee of what’s in the vial. The low price is the warning: there’s no licensed pharmacy, no provider, and no accountability behind it. This is not a patient route, and we don’t treat it as one.

Telehealth and concierge programs — roughly $250 to $550 per month. Online peptide services that offer the CJC-1295/ipamorelin combination typically bundle the medication, a prescriber relationship, and supplies into a monthly or multi-week price. As of mid-2026, a standard stack runs in the low-to-mid hundreds per month, with “advanced” stacks and concierge tiers climbing toward and past $550. These prices buy you a licensed provider and a managed program — though, as covered below, CJC-1295’s shaky legal footing means even these services sit in a gray zone.

In-person clinics — roughly $285 to $800+ per cycle or month. Brick-and-mortar wellness and longevity clinics tend to price per cycle or per package. Published examples in 2026 include single-peptide cycles starting around $445 for a multi-month course and bundled hormone-and-peptide packages near $675–$795. In-person clinics usually add an evaluation and sometimes an in-office body-composition scan, which is part of why they cost more than ship-to-your-door telehealth.

The headline takeaway: a $45 vial and a $450 cycle are not the same purchase with different markups. They’re different categories — an unregulated chemical versus a supervised medical service — and the price is mostly buying (or not buying) the oversight.

Why CJC-1295 is a special case on price

Here’s the piece most cost guides skip. With a peptide like BPC-157, the 2026 story is one of access reopening — it was removed from the FDA’s restricted Category 2 list in April 2026 and goes before the agency’s advisory committee in July 2026, so there’s a plausible near-term legal compounding pathway. CJC-1295 is not on that track.

CJC-1295 was referred to the FDA’s Pharmacy Compounding Advisory Committee back in 2024, and the committee recommended against adding it to the 503A bulk-substances list, citing safety and evidence concerns (FDA documentation from that review references adverse nonclinical findings). It is not among the twelve peptides removed from Category 2 in April 2026, and it is not on the July 2026 reclassification docket. In practical terms, that means there is no clean, settled basis for a compounding pharmacy to make it — even though a provider can write a prescription and some clinics continue to advertise it.

For your wallet, that has two consequences. First, pricing is inconsistent and unstable, because supply itself is unsettled — there’s no normal, regulated market setting a reference price. Second, when you pay a clinic for CJC-1295 in 2026, part of what you’re absorbing is regulatory risk: a service operating in a gray area, where availability can change and the pharmacy basis is precarious. That’s a real, if invisible, line item — and it’s the strongest argument for pricing CJC-1295 against its legal alternatives rather than in isolation.

Note: “A clinic offers it” and “it’s clearly legal to compound” are not the same statement in 2026. A provider can lawfully evaluate and prescribe; the unsettled part is whether a pharmacy has a clean basis to compound it. Ask the clinic directly how they source it.

Unbundling the bill: what you’re actually paying for

When a program quotes “$350 a month,” the medication is rarely the expensive part. Breaking the number into its components shows where the money goes — and where you have leverage.

• The medication itself is the smallest piece. The peptide input a pharmacy works with is inexpensive; it’s not what drives a several-hundred-dollar monthly price.
• The prescriber relationship is usually most of the bill. A licensed provider has to evaluate you, decide whether the therapy is appropriate, issue and manage the prescription, and follow up. That clinical time and liability is what you’re really buying, and it’s the difference between a vial and a program.
• Labs and monitoring vary. Some programs include baseline and follow-up bloodwork; others charge separately or skip it. A program that skips evaluation entirely is cheaper for a reason — and that reason is a red flag, not a saving.
• Supplies and logistics (reconstitution materials, syringes, sharps disposal, shipping) are bundled into most clinic and telehealth packages.
• An initial consultation typically runs about $99 to $400 depending on whether it’s telehealth or in-person; in-office visits with a scan sit at the higher end.

Read this way, the cheap vial isn’t undercutting the clinic on the same product — it’s selling you only the first bullet and stripping out every other one, including the one that keeps the therapy safe.

How CJC-1295 prices compare to the legal alternatives

Because CJC-1295’s own legal supply is unsettled, the most useful price comparison isn’t another CJC-1295 quote — it’s the related peptides you can obtain through a clean pathway. They sit in the same growth-hormone-releasing family and are often what a provider will steer toward.

Sermorelin is the obvious one. It’s a related growth-hormone-releasing peptide that can be legally compounded with a prescription, and it’s widely available through telehealth at roughly $150 to $225 per month, with in-clinic models running higher (up to about $500 depending on location and program). For many people researching CJC-1295, sermorelin is the cheaper and cleaner option, which reframes the whole cost question.

Tesamorelin (Egrifta) is the FDA-approved member of this family, approved for a specific indication. As an approved drug prescribed and dispensed through normal channels for that use, it’s the gold standard on legitimacy — but it’s also typically the most expensive, with telehealth quotes around $200–$400 per month and concierge pricing climbing well past $1,000. Off-label and anti-aging use is a different, unapproved context with its own cost and access picture.

The honest framing: when someone is drawn to CJC-1295 partly on price, comparing a gray-market vial to a sermorelin program often flips the math. A legal, supervised sermorelin course can land near the cost of a “research” CJC-1295 habit once you account for the pharmacy, the provider, and not gambling on an unverified injectable.

Insurance, HSA, and FSA: why this is out of pocket

Plan on paying for CJC-1295 yourself. Because it isn’t FDA-approved, insurance does not cover it for wellness, longevity, or anti-aging use — there’s no approved indication to bill against. This is a sharp contrast with GLP-1 weight-loss drugs, which are covered by some plans for approved indications; peptides like CJC-1295 have no equivalent path.

A health savings account (HSA) or flexible spending account (FSA) may sometimes be usable, but it’s conditional, not automatic. You’d generally need a valid prescription and, often, a letter of medical necessity from your provider, and even then administrators can decline. Treat HSA/FSA eligibility as “possible, ask first,” not as a built-in discount.

Red flags hiding in the price

A few pricing signals reliably point to the wrong end of the market:

• Strikingly cheap, no evaluation. If a vial is well under typical clinic input cost and nobody has assessed you, the low price reflects missing safeguards, not efficiency.
• “Research use only” / overseas import. Vials shipped from overseas or sold “for research” sidestep the entire regulated supply chain. The low cost is the absence of oversight — and of any guarantee of identity, purity, or sterility.
• Pay-and-inject with no provider. Any service that takes payment and ships without a real evaluation is selling convenience by removing the part that keeps you safe.
• Prices that seem to change weekly. Some volatility is expected here precisely because the legal supply is unsettled — but wildly shifting, opaque pricing is a reason to slow down and ask the clinic exactly how they source and compound it.

Cost matters, but for an unapproved injectable in an unsettled legal category, the cheapest number on the page is usually the most expensive mistake. The right starting move isn’t to find the lowest price — it’s to talk to a licensed provider, price the legal alternatives honestly, and decide from there.